Clinical trials: Male Breast Carcinoma
Breast Cancer
S0511, Goserelin and Anastrozole in Treating Men With Recurrent or Metastatic Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using goserelin and anastrozole may fight breast cancer by blocking the use of estrogen by the tumor cells.
- Trial name
- NCT00217659
- Testing
- anastrozole, goserelin acetate
- Where
- 57 sites in United States
- Sponsor
- SWOG Cancer Research Network
Breast Cancer, Prostate Cancer
HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)
The purpose of this study is to understand the safety and estimate the efficacy of anti-CD3 x anti-HER2 bispecific antibody (HER2Bi) armed fresh peripheral blood mononuclear cells (HER2 FPBMC) for patients with metastatic breast…
- Trial name
- NCT07441889
- Testing
- HER2 FPBMC
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Virginia
Breast Cancer (Triple Negative Breast Cancer (TNBC)), Renal Cell Carcinoma (Kidney Cancer)
Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment and work by blocking protein interactions that normally prevent the immune system from recognizing and destroying cancer cells.
- Conditions
- Breast Cancer (Triple Negative Breast Cancer (TNBC)), Renal Cell Carcinoma (Kidney Cancer), Melanoma (Skin Cancer), Non-Small Cell Lung Cancer
- Trial name
- NCT07555210
- Testing
- Dual-Energy X-ray Absorptiometry (DXA), High Resolution peripheral Quantitative Computed Tomography (HRpQCT)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Jessica Mezzanotte Sharpe
Breast Cancer, Colo-rectal Cancer
Interventional Study on DEterminants and Factors of Physical ACtivity After Treatments in Oncology
Benefits of physical activity (PA) as supportive care in cancer have been widely demonstrated by the scientific community. However, survivors who have completed chemo-radio-immunotherapy treatments doesn't achieve PA…
- Conditions
- Breast Cancer, Colo-rectal Cancer, Lung Cancer, Prostate Cancer
- Trial name
- DEFACTO2 (NCT05354882)
- Testing
- Physical activity program
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Université Sorbonne Paris Nord
Breast Cancer
Phase II Bevacizumab + Tax In Advanced Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways.
- Trial name
- NCT00027885
- Testing
- bevacizumab, cyclophosphamide, docetaxel
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- Case Comprehensive Cancer Center
Breast Carcinoma, Colon Carcinoma
Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
This research trial studies how well biospecimen collection works in identifying genetic changes in patients with breast, prostate, colorectal, liver, or kidney cancer or multiple myeloma undergoing surgery.
- Conditions
- Breast Carcinoma, Colon Carcinoma, Invasive Carcinoma, Kidney Carcinoma
- Trial name
- NCT04955808
- Testing
- Biospecimen Collection, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 2,400 people
- Sponsor
- National Cancer Institute (NCI)
High Cholesterol, High Blood Pressure
Online Trial Examining Validity and Reliability of the Shared Decision Making Process Survey
The purpose of this study is to survey a sample of adults who have recently made a decision about treatment of high cholesterol or high blood pressure or a decision about screening for colorectal cancer, breast cancer, or…
- Conditions
- High Cholesterol, High Blood Pressure, Colorectal Cancer, Breast Cancer
- Trial name
- NCT04317690
- Where
- United States
- Volunteers
- 539 people
- Sponsor
- Massachusetts General Hospital
Breast Cancer, Kidney Cancer
Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma
RATIONALE: Interferon alfa may interfere with the growth of cancer cells and slow the growth of cancer. PURPOSE: This phase I trial is studying the side effects and best dose of interferon alfa in treating patients with stage IV…
- Conditions
- Breast Cancer, Kidney Cancer, Lymphoma, Melanoma
- Trial name
- IFNa (NCT00276536)
- Testing
- recombinant interferon alpha-1b, IFN
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- The Cleveland Clinic
Breast Cancer, Prostate Cancer
Behavioral Weight Loss Program for Cancer Survivors in Maryland
Behavioral Weight Loss for Overweight and Obese Cancer Survivors in Maryland: A Demonstration Project
- Conditions
- Breast Cancer, Prostate Cancer, Melanoma (Skin), Endometrial Cancer
- Trial name
- ASPIRE (NCT04534309)
- Testing
- Written Weight Loss Material, Weight Loss App, Behavioral Lifestyle Weight Loss Intervention (Coaching)
- Where
- United States
- Volunteers
- 340 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
HER2-positive Breast Cancer, Male Breast Cancer
Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer
This phase II trial is studying how well vaccine therapy works in treating patients receiving trastuzumab for HER2-positive stage IIIB- IV breast cancer.
- Conditions
- HER2-positive Breast Cancer, Male Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
- Trial name
- NCT00343109
- Testing
- HER-2/neu intracellular domain protein, leukapheresis, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Washington
Cervical Cancer, Lung Cancer
Internet-based System for Cancer Patients to Self-report Toxicity
Cancer patients may develop side effects during treatment, such as nausea, pain, fatigue, diarrhea, constipation, or shortness of breath.
- Conditions
- Cervical Cancer, Lung Cancer, Prostate Cancer, Vaginal Cancer
- Trial name
- NCT00578006
- Testing
- Questioners, STAR website
- Where
- United States
- Volunteers
- 1,007 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00482755
- Testing
- sunitinib malate, immunohistochemistry staining method, laboratory biomarker analysis
- Where
- 2 sites in Canada
- Volunteers
- 4 people
- Sponsor
- NCIC Clinical Trials Group
Ovarian Cancer, Breast Cancer
'OLAP' (OLAparib Regulatory Post-marketing Surveillance)
The objectives of this study are to assess safety and effectiveness of Lynparza tablet (olaparib, hereinafter "the study drug") in a real world setting in patients who are prescribed with the study drug according to the approved…
- Conditions
- Ovarian Cancer, Breast Cancer, Prostate Cancer, Pancreatic Cancer
- Trial name
- OLAP (NCT04553926)
- Where
- 18 sites in South Korea
- Volunteers
- 661 people
- Sponsor
- AstraZeneca
Male Breast Cancer
Male breAsT cAncer preDisposition Factor: Creation of a Control Cohort 2
This is an interventional, prospective, single-center study designed to collect and describe genetic, environmental and psychosocial control data from male participants.
- Trial name
- MATADOR2 (NCT07558343)
- Testing
- Questionnaire completion, Genetic analysis (WES)
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Institut Claudius Regaud
Breast Cancer
PET Scans in Patients With Locally Advanced Breast Cancer
RATIONALE: Imaging procedures such as PET scans may improve the ability to monitor the effectiveness of chemotherapy for locally advanced breast cancer.
- Trial name
- NCT00109785
- Testing
- positron emission tomography, fludeoxyglucose F 18, iodine I 124 iododeoxyuridine
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, Non-small Cell Lung Cancer
Study to Evaluate the Safety of Nanoxel M Inj.
Study to evaluate the safety of Nanoxel M inj. administration in patients.
- Conditions
- Breast Cancer, Non-small Cell Lung Cancer, Prostate Cancer, Ovarian Cancer
- Trial name
- NCT04066335
- Where
- South Korea
- Volunteers
- 1,498 people
- Sponsor
- Samyang Biopharmaceuticals Corporation
Breast Cancer, Male
Study on the Progress of Breast Cancer Cases in Males and the Assessment of Relapse Risk
An observational, Other Designs (OD) post-marketing, multicenter study, which will obtain retrospective data from male patients diagnosed with invasive breast cancer between 2000 and 2019 in the medical oncology departments of…
- Trial name
- NCT03800355
- Where
- 54 sites in Spain
- Volunteers
- 777 people
- Sponsor
- Spanish Breast Cancer Research Group
Metastatic Breast Cancer, Metastatic Prostate Cancer
First-in-human Diagnostic Imaging Profile of the Theranostic Pair [68Ga]Ga-DOTA-STR-17126 and Low Dose [177Lu] Lu-DOTA-STR-17126 in Patients With Advanced or Metastatic Cancer
This is an open-label, first-in-human, exploratory Phase 0 study evaluating the safety and diagnostic imaging performance of the DOTA-STR-17126 theranostic pair in patients with advanced or metastatic breast or prostate cancer.
- Conditions
- Metastatic Breast Cancer, Metastatic Prostate Cancer, GRPR-Targeted Molecular Imaging, Theranostic Radiopharmaceuticals
- Trial name
- DOTA-STR-17126 (NCT07608848)
- Testing
- [177Lu]Lu-DOTA-STR-17126, [68Ga]Ga-DOTA-STR-17126
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- Integrated Haematology and Oncology Network
Renal Cell Carcinoma, Soft Tissue Sarcoma
HYPAZ: Hypertension Induced by Pazopanib
Pazopanib is a new cancer drug that works by limiting the growth of new blood vessels in tumours. About half of patients who take pazopanib develop high blood pressure (hypertension).
- Conditions
- Renal Cell Carcinoma, Soft Tissue Sarcoma, Glioblastoma, Ovarian Cancer
- Trial name
- HYPAZ (NCT01392352)
- Testing
- Pazopanib
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Cancer
Study of Information Received About Fertility and Infertility in Patients Who Have Finished Treatment for Cancer
RATIONALE: Learning about the amount of information on fertility and infertility by patients before they received treatment for cancer in a comprehensive cancer center may help doctors plan the best treatment.
- Trial name
- NCT01295463
- Testing
- questionnaire administration, study of socioeconomic and demographic variables, assessment of therapy complications
- Where
- Spain
- Volunteers
- 96 people
- Sponsor
- Institut Català d'Oncologia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.